Acquired epidermodysplasia verruciformis in an HIV-positive patient

International Journal of STD and AIDS

Volumn 27, Issue 11, 2016, Pages 1023-1025

  Lau, Carmen ^a   Acharya, Sashi ^a   Arumainayagam, Joseph T ^a   Kasparis, Christos ^a   Dhesi, I ^a  

^a MANOR HOSPITAL   (United Kingdom)

Author keywords

epidermodysplasia verruciformis; HPV; Human immunodeficiency virus; human papillomavirus

Indexed keywords

ATAZANAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; IMIQUIMOD; RALTEGRAVIR; RITONAVIR; AMINOQUINOLINE DERIVATIVE; IMMUNOLOGICAL ADJUVANT;

ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; EPIDERMODYSPLASIA VERRUCIFORMIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERKERATOSIS; KERATINOCYTE; PAPILLOMAVIRUS INFECTION; PAPULE; PRIORITY JOURNAL; PUNCH BIOPSY; VERTICAL TRANSMISSION; VIRUS LOAD; WART VIRUS; ZIMBABWEAN; COMPLICATION; HIV INFECTIONS; IMMUNOCOMPROMISED PATIENT; PATHOLOGY; SKIN; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; AMINOQUINOLINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EPIDERMODYSPLASIA VERRUCIFORMIS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; SKIN; TREATMENT OUTCOME;

EID: 84988421863     PISSN: 09564624     EISSN: 17581052     Source Type: Journal    
DOI: 10.1177/0956462415613933     Document Type: Article

References (11)

1. Patel T, Katie Morrison L, Rady P. Epidermodysplasia verruciformis and susceptibility to HPV. Dis Markers 2010; 29: 199–206.
2. Rezaei N, Hedayat M, Aghamohammadi A. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J Allergy Clin Immunol 2011; 127: 1329–1341.
3. Rogers HD, MacGregor JL, Nord KM. Acquired epidermodysplasia verruciformis. J Am Acad Dermatol 2009; 60: 315–320.
4. Moore RL, de Schaetzen V, Joseph M. Acquired epidermodysplasia verruciformis syndrome in HIV-infected pediatric patients: prospective treatment trial with topical glycolic acid and human papillomavirus genotype characterization. Arch Dermatol 2012; 148: 128–130.
5. Jacobelli S, Laude H, Carlotti A. Epidermodysplasia verruciformis in human immunodeficiency virus-infected patients: a marker of human papillomavirus-related disorders not affected by antiretroviral therapy. Arch Dermatol 2011; 147: 590–596.
6. Gül U, Kiliç A, Gönül M. Clinical aspects of epidermodysplasia verruciformis and review of the literature. Int J Dermatol 2007; 46: 1069–1072.
7. Ramoz N, Rueda LA, Bouadjar B. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002; 32: 579–581.
8. Mermet I, Guerrini JS, Cairey-Remonnay S. Cervical intraepithelial neoplasia associated with epidermodysplasia verruciformis HPV in an HIV-infected patient: a manifestation of immune restoration syndrome. Eur J Dermatol 2007; 17: 149–152.
9. Iarikov D, Duke W, Skiest D. Extensive development of flat warts as a cutaneous manifestation of immune reconstitution syndrome. AIDS Read 2008; 18: 524–527.
10. King MD, Reznik DA, O'Daniels CM. Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002; 34: 641–648.
11. Davison SC, Francis N, McLean K. Epidermodysplasia verruciformis-like eruption associated with HIV infection. Clin Exp Dermatol 2004; 29: 311–312.